Healthcare shares are mixed in pre-market. In stocks news,
), which is developing medical devices using neuroblocking
technology to treat obesity and metabolic diseases, said it
believes it remains on track for a decision from the U.S. Food and
Drug Administration on its Maestro Rechargeable System in the first
half of next year.
ETRM is up more than 3% pre-market, though remain near the
bottom of their 52-week range of $0.81 - $4.14.
And, Teva Pharmaceutical Industries Ltd. (
) announced the launch of the generic equivalent to ADENOSCAN
(adenosine injection) in the United States. Teva was first to file,
making the product eligible for 180 days of marketing
Marketed by Astellas Pharma, ADENOSCAN had annual sales of
approximately $65 million in the United States as of June 30, 2013.
TEVA edged up by $0.10 to $38.11 in pre-market trade.
Finally, Sanofi (
) reports new GetGoal-L sub-analysis results showing that
reductions in HbA1c with Lyxumia, when added to basal insulin, were
greatest in patients with type 2 diabetes who had well-controlled
baseline fasting plasma glucose.
These findings are consistent with the efficacy profile of
Lyxumia, which shows a clinical and statistically significant
reduction in HbA1c across different patient populations. SNY is up
0.40% at $50.64.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.